tradmap

SRZN Surrozen, Inc./DE

$22.50 -0.29%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Surrozen, Inc./DE (SRZN) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $265 million. Shares last traded at $22.50, 35.4% below their 52-week high. Over the past year the stock is up 86.0%. Revenue declined 67.4% year over year.

Market Cap
$265M
Shares Out
11.8M
EPS (TTM)
$-26.13
P/E Ratio
P/S Ratio
22.98
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$34.82
52-Week Low
$11.30
Volume
22,186
Avg Vol (3m)
12,411.794

Performance

1W
-6.39%
1M
+2.53%
3M
-7.54%
6M
-20.70%
YTD
+3.76%
1Y
+85.99%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI. SRZN split history →

Technicals

RSI (14)
45.66
SMA (50)
$22.95
SMA (200)
$24.02
Price vs SMA50
-1.92%
Price vs SMA200
-6.31%
ATR (14)
$1.48

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$12M
Net Income
$-332M
Gross Margin
Operating Margin
-385.3%
Net Margin
Return on Equity
151.9%
Return on Assets
-287.3%
Current Ratio
12.14
Debt / Equity
-1.53
Revenue Growth (YoY)
-67.4%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-6.84 2026-08-06
Q1 2026 $-11.65 2026-05-06
FY 2025 $-32.37 2026-03-23
Q3 2025 $-8.49 2025-11-07
Q2 2026 $0.85 2026-08-06
Q1 2026 $-7.43 2026-05-06

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

SRZN vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
22.98 / 19.49 med
+18% premium
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.